Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944920 | 0.96 | POLB (0.41) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944810 | 0.96 | ALDH1A1 (0.42) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9945004 | 0.96 | ALDH1A1 (0.42) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944953 | 0.92 | ALDH1A1 (0.40) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944889 | 0.92 | ALDH1A1 (0.42) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944914 | 0.91 | ALDH1A1 (0.42) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944916 | 0.89 | ALDH1A1 (0.40) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944966 | 0.89 | ALDH1A1 (0.40) | ALDH1A1POLBRAB9ANPC1TAS1R3 | |
| SCHEMBL9944743 | 0.89 | MAPT (0.42) | ALDH1A1POLBRAB9ANPC1MAPT | |
| SCHEMBL9944912 | 0.89 | POLB (0.51) | ALDH1A1POLBRAB9ANPC1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885POLB 2315/4885RAB9A 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.